Geffen Residence & Renewal Ltd (TLV:GEFR)
Israel · Delayed Price · Currency is ILS · Price in ILA 65.40
+2.50 (3.97%)
Jul 31, 2025, 5:24 PM IDT
Sage Therapeutics Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2020 |
| 0.12 | 0.13 | 0.14 | 0.06 | 0.66 | 2.67 | Upgrade | |
Revenue Growth (YoY) | -18.02% | -7.75% | 136.67% | -90.88% | -75.33% | - | Upgrade |
Cost of Revenue | - | - | - | 5.99 | 10.88 | 1.9 | Upgrade |
Gross Profit | 0.12 | 0.13 | 0.14 | -5.93 | -10.22 | 0.77 | Upgrade |
Selling, General & Admin | 8.56 | 8.1 | 7.19 | 4.67 | 5.45 | 4.05 | Upgrade |
Other Operating Expenses | -1.31 | -1.15 | -0.27 | 8.27 | 4.49 | 0.89 | Upgrade |
Operating Expenses | 7.25 | 6.96 | 6.93 | 12.95 | 9.93 | 4.94 | Upgrade |
Operating Income | -7.14 | -6.83 | -6.78 | -18.88 | -20.16 | -4.17 | Upgrade |
Interest Expense | -3.93 | -4.1 | -1.3 | -0.4 | -0.91 | -1.28 | Upgrade |
Interest & Investment Income | 0.96 | 1.05 | 0.31 | 0.29 | 0.06 | 0.01 | Upgrade |
Other Non Operating Income (Expenses) | 3.77 | 3.77 | 1.1 | -0.03 | -0.05 | -2.96 | Upgrade |
EBT Excluding Unusual Items | -6.33 | -6.11 | -6.67 | -19.03 | -21.05 | -8.4 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | - | -0.55 | Upgrade |
Asset Writedown | -0.09 | -0.09 | - | - | - | -2.28 | Upgrade |
Other Unusual Items | - | - | - | - | - | -0.72 | Upgrade |
Pretax Income | -6.42 | -6.2 | -6.67 | -19.03 | -21.05 | -11.95 | Upgrade |
Income Tax Expense | -1.42 | -1.08 | -0.5 | - | 1.47 | -2.9 | Upgrade |
Earnings From Continuing Operations | -5.01 | -5.12 | -6.17 | -19.03 | -22.52 | -9.06 | Upgrade |
Earnings From Discontinued Operations | -0.01 | -0.05 | -0.98 | -1.06 | 9.94 | 0.8 | Upgrade |
Net Income to Company | -5.02 | -5.17 | -7.15 | -20.08 | -12.58 | -8.26 | Upgrade |
Minority Interest in Earnings | 0.1 | 0.1 | 0.24 | - | -0.84 | -0.55 | Upgrade |
Net Income | -4.92 | -5.07 | -6.91 | -20.08 | -13.43 | -8.81 | Upgrade |
Net Income to Common | -4.92 | -5.07 | -6.91 | -20.08 | -13.43 | -8.81 | Upgrade |
Shares Outstanding (Basic) | 214 | 218 | 216 | 99 | 88 | 75 | Upgrade |
Shares Outstanding (Diluted) | 214 | 218 | 216 | 99 | 88 | 75 | Upgrade |
Shares Change (YoY) | -6.40% | 1.15% | 116.97% | 12.88% | 17.70% | 713.15% | Upgrade |
EPS (Basic) | -0.02 | -0.02 | -0.03 | -0.20 | -0.15 | -0.12 | Upgrade |
EPS (Diluted) | -0.02 | -0.02 | -0.03 | -0.20 | -0.15 | -0.12 | Upgrade |
Free Cash Flow | -17.53 | -16.48 | -61.75 | -11.23 | -17.31 | -12.09 | Upgrade |
Free Cash Flow Per Share | -0.08 | -0.08 | -0.29 | -0.11 | -0.20 | -0.16 | Upgrade |
Gross Margin | 100.00% | 100.00% | 100.00% | - | - | 28.83% | Upgrade |
Operating Margin | -6150.86% | -5210.69% | -4776.76% | -31465.00% | -3063.07% | -156.39% | Upgrade |
Profit Margin | -4237.93% | -3872.52% | -4866.20% | -33470.00% | -2040.43% | -330.30% | Upgrade |
Free Cash Flow Margin | -15115.52% | -12580.15% | -43485.92% | -18715.00% | -2630.55% | -453.43% | Upgrade |
EBITDA | -6.95 | -6.58 | -6.27 | -14.91 | -17.76 | -0.33 | Upgrade |
EBITDA Margin | - | - | - | - | - | -12.41% | Upgrade |
D&A For EBITDA | 0.18 | 0.25 | 0.52 | 3.97 | 2.4 | 3.84 | Upgrade |
EBIT | -7.14 | -6.83 | -6.78 | -18.88 | -20.16 | -4.17 | Upgrade |
EBIT Margin | - | - | - | - | - | -156.39% | Upgrade |
Advertising Expenses | - | 0.16 | 0.19 | 0.08 | 0.18 | - | Upgrade |
Updated Aug 18, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.